Faisal Zain is a distinguished expert in healthcare innovation, specifically focused on the transformative intersection of medical technology and preventive diagnostics. With years of experience in the manufacturing and strategic deployment of medical devices, he has been a leading voice in the shift toward longitudinal health management. As we look at the changing demographics of the next few decades, Faisal’s work highlights a critical gap in our current medical infrastructure: the often-overlooked foundation of human mobility—our skeletal system. In this conversation, he explores why bone health is no longer a niche specialty but the next major pillar in the global pursuit of a longer, more functional healthspan.
Cardiovascular and metabolic health have long been the primary focus of preventive care, but we are seeing a significant shift toward skeletal health. How do you interpret this evolution in the healthcare landscape?
We are witnessing a natural progression in how we define a “healthy” life, moving from simply surviving to truly thriving in our later years. Forty years ago, the medical community was obsessed with cardiovascular health, and about twenty years ago, that focus shifted toward metabolic markers like blood sugar and cholesterol. Today, we realize that you can have the heart of a marathon runner and perfect glucose levels, yet still lose your entire quality of life because of a single hip fracture at age 85. This evolution is driven by the realization that longevity is meaningless without mobility; a strong skeleton is the structural requirement for the independence we all crave as we age. We are finally moving away from seeing bone density as a narrow concern for specialists and recognizing it as a fundamental pillar of lifelong health, much like we did with blood pressure decades ago.
The statistics surrounding bone health are quite alarming, yet it is often called a ‘silent’ crisis. What are the specific numbers driving the urgency for better diagnostic infrastructure?
The numbers are truly staggering when you look at them closely: right now, more than 60 million adults over the age of 50 in the United States alone are living with either osteoporosis or osteopenia. This isn’t just a local issue, as fragility fractures are happening globally at a rate of approximately 37 million every single year, which breaks down to about one fracture every second. For an individual, the odds are sobering, with one in two women and one in four men over 50 expected to suffer an osteoporotic fracture in their lifetime. These aren’t just minor injuries; a hip fracture in an older adult is one of the most reliable predictors of a rapid decline in independence and even mortality within the following year. This massive, unmet need is finally coming into the light because we can no longer ignore the physical and economic toll of a population that is living longer but breaking more easily.
You’ve identified several external factors—like the rise of GLP-1 medications and the menopause movement—as major catalysts for this shift. How are these trends specifically impacting our approach to bone density monitoring?
These two trends are creating a massive new cohort of at-risk patients who require immediate and ongoing skeletal monitoring. In the case of menopause, the decline in estrogen has a direct and often devastating impact on bone density, with some women losing up to 20% of their bone mass in the five to seven years following the transition. Simultaneously, the explosion of GLP-1 medications for weight loss, while beneficial for metabolic health, presents a double-edged sword because rapid weight loss is frequently accompanied by a significant loss of muscle mass and bone density. We are looking at tens of millions of people who are now indirectly becoming candidates for bone health monitoring because of these biological and pharmacological shifts. It has turned bone health from a “wait and see” issue into a proactive requirement for anyone undergoing significant hormonal changes or medical weight loss treatments.
AI is often discussed in broad terms, but in the context of bone health, it seems to be performing a very specific ‘detective’ role. Can you elaborate on how AI is unlocking data from existing medical scans?
AI is fundamentally democratizing the diagnostic process by finding value in data that we’ve already collected but previously ignored. Millions of CT scans are performed every year for unrelated reasons—things like kidney stones, abdominal pain, or trauma—and those scans have always contained vital bone density information that simply went unread by the human eye. We are now using AI to “mine” these routine scans for opportunistic osteoporosis screening, effectively catching at-risk patients without requiring them to schedule a separate, dedicated DEXA scan. This shift turns bone health into a longitudinal data point rather than a one-off test, and we expect dental X-rays to be the next frontier for this kind of hidden-data extraction. It’s a sensory shift for the clinician; instead of waiting for a fracture to signal a problem, the software alerts them to thinning bone structure during a routine check-up for something else entirely.
If we look at the current ‘preventive health stack’—the tools people use to manage their well-being—bone health is noticeably absent. What are the primary barriers preventing it from becoming a standard pillar of care?
The primary barrier has always been that bone health is “silent” and incredibly difficult to measure outside of a clinical setting. While people can track their steps, heart rate, and even glucose levels with a wearable, bone density has historically required a specialized, often inaccessible DEXA scan, leading to a total lack of ongoing tracking. There is also a persistent lack of consumer awareness regarding the consequences of low bone density; people simply don’t fear a fracture the way they fear a heart attack until it actually happens. Furthermore, for a long time, treatment options were seen as limited or reactive, which discouraged early intervention. However, with the arrival of new technologies, such as the FDA-cleared non-drug wearables that launched nationwide last year, we are finally giving consumers the tools to engage with their skeletal health proactively rather than waiting for a crisis.
Looking forward, you’ve spoken about a transition from treating a disease state like osteoporosis to focusing on mobility as a whole. What does this multimodal, proactive approach look like in practice?
The future of this field isn’t just about a single drug or a single test; it’s about a comprehensive strategy that prioritizes movement and independence. This multimodal approach combines earlier intervention—using AI to catch bone loss years before a fracture occurs—with a lifestyle-integrated treatment plan that includes targeted nutrition, exercise, and fall-risk reduction. We are also seeing a shift toward “optimized treatment,” where doctors use longitudinal data to sequence therapies based on an individual’s specific risk factors, much like they do for managing blood pressure. By integrating monitoring into the daily lives of patients, especially those on GLP-1s or going through menopause, we can adjust interventions in real-time. This ensures that the skeleton remains strong enough to support an active life, moving the goalpost from “not having osteoporosis” to “staying mobile and strong” for three or four decades of older age.
What is your forecast for the bone health sector over the next few years?
My forecast is that bone health will become as quantifiable and manageable as cardiovascular health, driven by a surge in both private investment and consumer demand. By 2050, the US population aged 65 and over is projected to reach 83.7 million people, and this demographic shift is making skeletal health an economic and social imperative that the healthcare system can no longer afford to ignore. We’ve already seen significant momentum with over $15 million in private capital and millions in NIH grants flowing into innovative solutions like the Osteoboost wearable, which proves there is a massive appetite for non-pharmacological interventions. We are at a tipping point where the combination of AI-driven diagnostics and accessible, consumer-friendly treatments will make fragility fractures a rare occurrence rather than an expected part of aging. Ultimately, I believe we are entering an era where maintaining a “skeletal age” that matches or beats one’s chronological age will be the new standard for a successful, healthy life.
